Talzenna (talazoparib)

News alerts, weekly reports and conference planners

Company:

BioMarin, Pfizer

Drug class:

PARP inhibitor

Related drugs:

BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide capsule Sensitive: A1 - Approval talazoparib + enzalutamide capsule Sensitive : A1	talazoparib + enzalutamide capsule Sensitive: A1 - Approval talazoparib + enzalutamide capsule Sensitive : A1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
TP53 mutation	HER2 Negative Breast Cancer	TP53 mutation	HER2 Negative Breast Cancer	talazoparib Resistant: B - Late Trials talazoparib Resistant : B	talazoparib Resistant: B - Late Trials talazoparib Resistant : B
BRCA1 mutation	Hormone Receptor Positive Breast Cancer	BRCA1 mutation	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B
BRCA2 mutation	Hormone Receptor Positive Breast Cancer	BRCA2 mutation	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	talazoparib + enzalutamide capsule Sensitive: B - Late Trials talazoparib + enzalutamide capsule Sensitive : B	talazoparib + enzalutamide capsule Sensitive: B - Late Trials talazoparib + enzalutamide capsule Sensitive : B
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
BRCA1 mutation	Solid Tumor	BRCA1 mutation	Solid Tumor	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
BRCA2 mutation	Solid Tumor	BRCA2 mutation	Solid Tumor	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1	talazoparib Sensitive: C1 - Off-label talazoparib Sensitive : C1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
HRD	Non Small Cell Lung Cancer	HRD	Non Small Cell Lung Cancer	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3
MYC amplification	Triple Negative Breast Cancer	MYC amplification	Triple Negative Breast Cancer	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3
FANCA mutation	HER2 Negative Breast Cancer	FANCA mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
PTEN mutation	HER2 Negative Breast Cancer	PTEN mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
ATR mutation	HER2 Negative Breast Cancer	ATR mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
CHEK2 mutation	HER2 Negative Breast Cancer	CHEK2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	talazoparib + gemtuzumab ozogamicin Sensitive: C3 – Early Trials talazoparib + gemtuzumab ozogamicin Sensitive : C3	talazoparib + gemtuzumab ozogamicin Sensitive: C3 – Early Trials talazoparib + gemtuzumab ozogamicin Sensitive : C3
BRCA wild-type	Breast Cancer	BRCA wild-type	Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3

Talzenna (talazoparib)

Associations
(81)

Associations
(81)

Talzenna (talazoparib)

Associations(81)

Associations(81)

Associations
(81)

Associations
(81)